Biogen at hold by Jefferies

Biogen Idec was rated at hold by Jefferies & Co., Inc. analyst Adam Walsh. Jefferies is forecasting first-quarter 2006 total revenue and earnings per share of $635 million and $0.48, respectively. The analyst's earnings-per-share estimate is in line with Street consensus. The company will report first-quarter results on April 26. Shares of the Cambridge, Mass., pharmaceutical company were down 67 cents, or 1.50%, at $44.08 on volume of 2,587,613 shares versus the three-month running average of 3,531,590 shares. (Nasdaq: BIIB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.